1. Preclinical evaluation of188Re-HYNIC-PSMA as a novel therapeutic agent.
- Author
-
Hadisi, Maliheh, Vosoughi, Naser, Yousefnia, Hassan, Bahrami-Samani, Ali, Zolghadri, Samaneh, Vosoughi, Sara, and Alirezapour, Behrouz
- Subjects
- *
RADIOCHEMICAL purification , *QUALITY control , *RADIOLABELING , *HIGH performance liquid chromatography - Abstract
In this study, optimized preparation, quality control, cell assessments and biostribution of 188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods. 188Re-HYNIC-PSMA was stable both in PBS (4 °C) and in human serum (37 °C) even after 48 h. The results showed the complex was cleared from the blood very fast via urinary track. This new radiolabeled compound has a high potential to be considered as an agent for the treatment of patients with PSMA expressing tumors however more biological studies are still needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF